FINWIRES · TerminalLIVE
FINWIRES

Trident公司在薩斯喀徹溫省Contact Lake專案鑽探中取得了迄今為止最佳鑽探結果

By

-- Trident Resources (ROCK.V) 週三宣布,該公司在薩斯喀徹溫省的 Contact Lake 金礦項目取得了迄今為止最佳鑽探結果。 Trident 在 CL26036 號鑽孔中鑽取了 51.83 公尺厚、金品位為 15.11 克/噸 (g/t) 的礦段,該公司表示,這「在加拿大金礦勘探中實屬罕見的高品位礦段」。 該公司還報告稱,在 Bakos 剪切帶內部及鄰近區域,一片剪切程度不一的圍岩中也發現了高品位金礦。其他結果包括 21.50 公尺厚、金品位為 5.07 克/噸的礦段。 「這些結果尤其引人注目,因為礦化體在各個方向都尚未封閉,這凸顯了我們看到的整個礦區巨大的成長潛力,」執行長 Jon Wiesblatt 表示。 「我們在鑽探中發現,多條平行剪切帶附近存在高品位金礦,這令人振奮,因為這些剪切帶在深處的潛在匯聚點代表著一個尚未開發的、高優先級的鑽探目標,」維斯布拉特補充道。 此外,康塔特湖區域還有15個鑽孔待鑽,目標是高品位BK3礦帶。該公司還計劃在夏季和秋季開展鑽探項目。

Related Articles

Australia

Ryde Signs MoU With VinaTaxi to Explore Vietnam Opportunities

Ryde Group (RYDE) said Wednesday that it has signed a memorandum of understanding with VinaTaxi to explore strategic collaboration opportunities in Vietnam.The areas of exploration include the deployment of Ryde's platform within VinaTaxi's taxi fleet, and the development of an electric motorcycle ride-hailing ecosystem, the company said.Price: $1.20, Change: $+0.02, Percent Change: +1.61%

$RYDE
Research

Research Alert: Biogen Q1 Earnings: Strong Beat Overshadowed By Lowered Full-year Eps Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Biogen delivered strong Q1 2026 results with non-GAAP EPS of $3.57 (+18% Y/Y) significantly exceeding the consensus of $2.95, while revenue of $2.478B (+2% Y/Y) beat expectations of $2.2B. Growth products sustained impressive momentum, generating $851M (+12% Y/Y), now representing one-third of total revenue, with LEQEMBI collaboration revenue up 80% Y/Y to $60M and the MS franchise showing better-than-expected resilience at $779M (-4% Y/Y). We view the continued acceleration of growth products as demonstrating successful portfolio diversification away from MS dependence. Management downgraded 2026 non-GAAP EPS guidance to $14.25-$15.25 from $15.25-$16.25, primarily reflecting acquired IPR&D charges. The proposed $5.6B Apellis acquisition, expected to close in Q2 2026, will add SYFOVRE and EMPAVELI to the growth portfolio and is anticipated to be accretive in 2027, in our view. We expect the combined revenue from these assets to grow in the mid-to-high teens for at least the next two years.

$BIIB
Australia

Emergent BioSolutions Signs $50 Million Contract to Support SAB Biotherapeutics' Lead Program

Emergent BioSolutions (EBS) said Wednesday it has signed a $50 million multi-year agreement with SAB Biotherapeutics (SABS) to help advance SAB-142 lead program in clinical development for autoimmune type 1 diabetes.Under the agreement, $36 million is contingent on future regulatory approval and downstream milestones, according to a statement.Emergent BioSolutions will provide end-to-end development and manufacturing services that are compliant with current good manufacturing practices, the company said.Price: $8.17, Change: $-0.07, Percent Change: -0.79%

$EBS$SABS